Fulgent Genetics, Inc. (FLGT) stock
FLGTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3047% below fair value
$25.13+0.92 (+3.80%)
Close on Nov 18, 2026Market cap $691.46MP/E –Yield –
Fulgent Genetics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Fulgent Genetics's pe ratio was 6.5× on Apr 28, 2023, against 3.3× a year earlier. Over the last 3 years it ranged from 3.0× to 333.7×, with a median of 5.2×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Apr 28, 2023 | 6.5× | +3.0 |
| 2022 | Dec 30, 2022 | 3.4× | −1.8 |
| 2021 | Dec 31, 2021 | 5.2× | −20.6 |
| 2020 | Dec 31, 2020 | 25.8× | – |
See a number that looks wrong?